

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: JOLT HEALTH INC.(the "Issuer").

Trading Symbol: CSE: JOLT

Number of Outstanding Listed Securities: 127,289,723

Date: April 4, 2024

Month of March 2024

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.
 - Jolt Health is a leading life sciences company focused on healthcare, biotechnology and artificial intelligence. The company currently holds exclusive licenses for innovative therapeutic and pharmaceutical products throughout Europe, the UK, and North America. The company is committed to transforming the industry through research, collaboration, and technological advancement, shaping the future of healthcare worldwide.
2. Provide a general overview and discussion of the activities of management.
 - The Company is actively expanding its health and wellness portfolio by seeking opportunities in AI drug development and pharmaceutical sectors, while focusing on companies with tangible assets and a commitment to health and wellness.
 - The company has announced a private placement financing to raise up to \$500,000 and welcomed Mr. Cody Corrubia to its board, signifying strategic moves to bolster growth and shareholder value in the burgeoning health market.
 - The company completed its previously announced non-brokered private placement, raising \$500,000 by issuing 50,000,000 units at \$0.01 each, with each unit comprising a common share and half a warrant, enabling further share purchases at \$0.05 for two years. The proceeds are earmarked for general working capital and debt repayment, excluding officer salaries or investor relations payments, with securities subject to trading restrictions until July 28, 2024.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs, and acquisitions of any new properties and attach any mineral, oil, gas, or other reports required under Ontario securities law. **N/A**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned. **N/A**
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship. **N/A**
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced. **N/A**
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship. **N/A**
8. Describe the acquisition of new customers or loss of customers. **N/A**
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks. **N/A**
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
Hire:
- Cody Corrubia – Director
Termination:
- Mark Tommasi - Director
11. Report on any labour disputes and resolutions of those disputes if applicable. **N/A**
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
N/A
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness. **N/A**
14. Provide details of any securities issued and options or warrants granted.

Stocks Issued:

Number Issued	Details of Issuance

50,000,000	Private placement at the price of \$0.01 per unit
------------	---

Warrants Issued:

Number Issued	Details of Issuance
25,000,000	Exercise price for one additional common share for \$0.05 for a period of 2 years from the date of closing

15. Provide details of any loans to or by Related Persons. **N/A**
16. Provide details of any changes in directors, officers or committee members.
 - Cody Corrubia serves in the capacity of Director.
 - Termination of Mark Tommasi's tenure as Director.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
 - **Trends that are likely to impact the Issuer include: COVID-19 The outbreak of the coronavirus ("COVID-19") pandemic has impacted the Issuer's plans and activities.**

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 4th, 2024

Gerald Tritt
Name of Director or Senior
Officer

Signature
CEO

Official Capacity

<i>Issuer Details</i> Name of Issuer Jolt Health Inc.	For Month End March	Date of Report YY/MM/DD 24/04/04
Issuer Address: 1780 - 355 Burrard Street		
City/Province/Postal Code Vancouver/ BC/ V6C 2G8 Canada	Issuer Fax No. ()	Issuer Telephone No. (604)343-2977
Contact Name Gerald Tritt	Contact Position IR	Contact Telephone No. (604)343-2977
Contact Email Address info@jolt-health.com	Web Site Address https://jolt-health.com/	